Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Apr 30, 2022 10:47am
272 Views
Post# 34644735

RE:RE:Theralase Releases Results

RE:RE:Theralase Releases Results24% is 5% better than Keytruda achieved at 360 days and that was good enough for FDA approval, despite 8% serious side effects and multiple treatments. Plus, the FDA knows 12 of the first 25 TLD1433 patients were undertreated so the ultimate 450 day CR results will be higher as more and more patients receive the optimized treatment. In my opinion Theralase will receive accelerated approval in early 2023, just as Theralase projected in the tumeline.
riverrrow wrote: 24% CR at 450 days for a 2x treatment application with very little side effects seems pretty good to me.  I suspect some tweaking of the procedure could bring up the CR.  GLTA.


<< Previous
Bullboard Posts
Next >>